StockData

Seres Therapeutics vs Xenetic Biosciences

MCRB and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MCRB and XBIO compare

Seres Therapeutics is the larger company, worth 3.7 times as much as Xenetic Biosciences ($14.0M against $3.8M).

Xenetic Biosciences keeps more of each dollar of sales as profit, with a net margin of −75.9% compared with −1193% at Seres Therapeutics.

Xenetic Biosciences scores higher on the StockData Score (12 against 6 for Seres Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMCRBXBIO
Size and price
Market cap$14.0M$3.8M
Share price$1.41$1.61
Change, 1 year−91.5%−38.1%
Change, 5 years−99.2%−88.9%
Beta (5Y)0.281.14
Employees662
StockData Score
Total score612 (better)
Valuation score13 (better)
Growth score02 (better)
Performance score02 (better)
Health score55
Dividend score00
Valuation
P/S7.4×1.2× (better)
P/B0.4× (better)0.6×
FCF yield−366%–
Fair value–$4.53
Margin of safety–64.4%
Growth
Revenue growth (TTM)–33.3%
Revenue growth, 5Y average−52.7%46.8% (better)
Net income growth (TTM)−126%–
EPS growth (TTM)−121%–
Profitability
Operating margin−4463%−81.0% (better)
Net margin−1193%−75.9% (better)
FCF margin−2724%–
Return on equity−66.6%−47.0% (better)
Financial health
Debt / equity0.000.00
Current ratio2.117.43 (better)
Altman Z-score−15.93 (better)−37.70
Piotroski F-score6 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions22.9%6.5%
Held by insiders2.3%12.2%
Insider net buying, 12 months−$10.0K–
Short interest, % of float3.5%1.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.